Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9904	Companies
199560	Keywords
130432	Articles
106067	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/17/2024 at 17:00, 1 year 5 months ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns
BRIEF

published on 09/12/2024 at 12:05, 1 year 5 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
PRESS RELEASE

published on 09/12/2024 at 12:00, 1 year 5 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 1 year 5 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 5 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License
BRIEF

published on 09/05/2024 at 14:05, 1 year 5 months ago

EMA Recommends Authorization of Moderna's Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Authorization COVID-19 Vaccine Moderna EMA SARS-CoV-2 Variant
PRESS RELEASE

published on 09/05/2024 at 14:00, 1 year 5 months ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 receives positive opinion from CHMP for European Commission authorization decision for 2024-2025 vaccination season

COVID-19 Vaccine European Commission Moderna MRNA Spikevax
BRIEF

published on 09/03/2024 at 14:35, 1 year 5 months ago

Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

COVID-19 Moderna Vaccine JN.1 Variant MHRA
PRESS RELEASE

published on 09/03/2024 at 14:30, 1 year 5 months ago

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants

COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF

published on 09/02/2024 at 13:05, 1 year 5 months ago

Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1

Accesswire

Published on 02/21/2026 at 00:45, 1 day 13 hours ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 1 day 13 hours ago

Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:15, 1 day 15 hours ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 1 day 15 hours ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 1 day 15 hours ago

Organto Foods Completes Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 02/22/2026 at 12:19, 1 hour 56 minutes ago

Elmos Semiconductor SE: Generational change initiated in the Supervisory Board
Published on 02/22/2026 at 10:09, 4 hours 6 minutes ago

Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 02/21/2026 at 12:00, 1 day 2 hours ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/20/2026 at 18:36, 1 day 19 hours ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 day 19 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 02/20/2026 at 19:29, 1 day 18 hours ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 18:00, 1 day 20 hours ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 09:28, 2 days 4 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
Published on 02/20/2026 at 07:30, 2 days 6 hours ago

Announcement of share buyback in the context of a share purchase plan
Published on 02/20/2026 at 07:30, 2 days 6 hours ago

EURAZEO COMPLETES THE SALE OF EX NIHILO TO L CATTERTON

View all LES ECHOS COMFI WIRE